nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—Topoisomerase Inhibitors—Irinotecan—colon cancer	0.385	1	CiPCiCtD
Doxorubicin—liver cancer—colon cancer	0.0653	0.223	CtDrD
Doxorubicin—breast cancer—colon cancer	0.0552	0.189	CtDrD
Doxorubicin—stomach cancer—colon cancer	0.0476	0.163	CtDrD
Doxorubicin—RALBP1—Vincristine—colon cancer	0.0465	0.272	CbGbCtD
Doxorubicin—ovarian cancer—colon cancer	0.0444	0.152	CtDrD
Doxorubicin—pancreatic cancer—colon cancer	0.0444	0.152	CtDrD
Doxorubicin—ABCB1—colon cancer	0.0435	1	CbGaD
Doxorubicin—lung cancer—colon cancer	0.0358	0.122	CtDrD
Doxorubicin—ABCC10—Vincristine—colon cancer	0.0171	0.1	CbGbCtD
Doxorubicin—ABCC3—Fluorouracil—colon cancer	0.0118	0.069	CbGbCtD
Doxorubicin—ABCC3—Vincristine—colon cancer	0.0107	0.0629	CbGbCtD
Doxorubicin—ABCC10—Methotrexate—colon cancer	0.0103	0.0605	CbGbCtD
Doxorubicin—ABCB11—Vincristine—colon cancer	0.00927	0.0544	CbGbCtD
Doxorubicin—ABCC1—Irinotecan—colon cancer	0.00753	0.0442	CbGbCtD
Doxorubicin—ABCC1—Vincristine—colon cancer	0.00659	0.0386	CbGbCtD
Doxorubicin—ABCC3—Methotrexate—colon cancer	0.00649	0.0381	CbGbCtD
Doxorubicin—ABCC2—Irinotecan—colon cancer	0.00558	0.0327	CbGbCtD
Doxorubicin—ABCG2—Irinotecan—colon cancer	0.00504	0.0296	CbGbCtD
Doxorubicin—ABCC2—Vincristine—colon cancer	0.00487	0.0286	CbGbCtD
Doxorubicin—ABCG2—Fluorouracil—colon cancer	0.00484	0.0284	CbGbCtD
Doxorubicin—ABCG2—Vincristine—colon cancer	0.00441	0.0258	CbGbCtD
Doxorubicin—ABCC1—Methotrexate—colon cancer	0.00399	0.0234	CbGbCtD
Doxorubicin—CYP2B6—Irinotecan—colon cancer	0.00355	0.0208	CbGbCtD
Doxorubicin—ABCC2—Methotrexate—colon cancer	0.00295	0.0173	CbGbCtD
Doxorubicin—ABCG2—Methotrexate—colon cancer	0.00267	0.0156	CbGbCtD
Doxorubicin—NOS1—myenteric nerve plexus—colon cancer	0.0024	0.0798	CbGeAlD
Doxorubicin—ABCB1—Irinotecan—colon cancer	0.00182	0.0107	CbGbCtD
Doxorubicin—ABCB1—Vincristine—colon cancer	0.00159	0.00932	CbGbCtD
Doxorubicin—ABCB11—bile—colon cancer	0.00136	0.0451	CbGeAlD
Doxorubicin—NOS3—vein—colon cancer	0.00118	0.0391	CbGeAlD
Doxorubicin—CYP3A4—Irinotecan—colon cancer	0.00109	0.00639	CbGbCtD
Doxorubicin—ABCB1—Methotrexate—colon cancer	0.000962	0.00564	CbGbCtD
Doxorubicin—CYP3A4—Vincristine—colon cancer	0.000952	0.00558	CbGbCtD
Doxorubicin—NOS3—umbilical vein—colon cancer	0.000855	0.0284	CbGeAlD
Doxorubicin—ABCC2—bile—colon cancer	0.000691	0.0229	CbGeAlD
Doxorubicin—NOS1—endothelium—colon cancer	0.000533	0.0177	CbGeAlD
Doxorubicin—SLC22A16—renal system—colon cancer	0.000507	0.0168	CbGeAlD
Doxorubicin—CBR3—embryo—colon cancer	0.000501	0.0166	CbGeAlD
Doxorubicin—NOS1—blood vessel—colon cancer	0.000491	0.0163	CbGeAlD
Doxorubicin—NOS3—endothelium—colon cancer	0.000405	0.0135	CbGeAlD
Doxorubicin—ABCB8—renal system—colon cancer	0.000394	0.0131	CbGeAlD
Doxorubicin—AURKA—Topotecan—Irinotecan—colon cancer	0.000385	0.397	CbGdCrCtD
Doxorubicin—SLC22A16—bone marrow—colon cancer	0.000383	0.0127	CbGeAlD
Doxorubicin—NOS3—blood vessel—colon cancer	0.000374	0.0124	CbGeAlD
Doxorubicin—AKR1A1—smooth muscle tissue—colon cancer	0.000304	0.0101	CbGeAlD
Doxorubicin—AKR1A1—renal system—colon cancer	0.000293	0.00972	CbGeAlD
Doxorubicin—CBR3—vagina—colon cancer	0.000275	0.00912	CbGeAlD
Doxorubicin—NQO1—gall bladder—colon cancer	0.000267	0.00887	CbGeAlD
Doxorubicin—NDUFS7—renal system—colon cancer	0.000266	0.00883	CbGeAlD
Doxorubicin—AURKA—renal system—colon cancer	0.000247	0.00821	CbGeAlD
Doxorubicin—AKR1A1—lymphoid tissue—colon cancer	0.000243	0.00807	CbGeAlD
Doxorubicin—ABCB8—liver—colon cancer	0.000241	0.00799	CbGeAlD
Doxorubicin—AKR1A1—digestive system—colon cancer	0.00024	0.00797	CbGeAlD
Doxorubicin—ABCC3—gall bladder—colon cancer	0.00024	0.00796	CbGeAlD
Doxorubicin—NOS1—epithelium—colon cancer	0.000239	0.00794	CbGeAlD
Doxorubicin—NOS1—smooth muscle tissue—colon cancer	0.00023	0.00765	CbGeAlD
Doxorubicin—NDUFS2—smooth muscle tissue—colon cancer	0.000229	0.0076	CbGeAlD
Doxorubicin—NDUFS3—smooth muscle tissue—colon cancer	0.000226	0.00751	CbGeAlD
Doxorubicin—NOS1—renal system—colon cancer	0.000222	0.00737	CbGeAlD
Doxorubicin—AKR1A1—bone marrow—colon cancer	0.000221	0.00735	CbGeAlD
Doxorubicin—NDUFS2—renal system—colon cancer	0.00022	0.00732	CbGeAlD
Doxorubicin—AKR1C3—Vinblastine—Vincristine—colon cancer	0.00022	0.227	CbGdCrCtD
Doxorubicin—NDUFS7—digestive system—colon cancer	0.000218	0.00725	CbGeAlD
Doxorubicin—NDUFS3—renal system—colon cancer	0.000218	0.00723	CbGeAlD
Doxorubicin—AKR1A1—vagina—colon cancer	0.000212	0.00704	CbGeAlD
Doxorubicin—AURKA—lymphoid tissue—colon cancer	0.000205	0.00682	CbGeAlD
Doxorubicin—AURKA—digestive system—colon cancer	0.000203	0.00674	CbGeAlD
Doxorubicin—ABCC6—renal system—colon cancer	0.000202	0.0067	CbGeAlD
Doxorubicin—NDUFS7—bone marrow—colon cancer	0.000201	0.00668	CbGeAlD
Doxorubicin—YWHAG—smooth muscle tissue—colon cancer	0.000197	0.00655	CbGeAlD
Doxorubicin—NDUFS7—vagina—colon cancer	0.000193	0.0064	CbGeAlD
Doxorubicin—YWHAG—renal system—colon cancer	0.00019	0.0063	CbGeAlD
Doxorubicin—AURKA—bone marrow—colon cancer	0.000187	0.00621	CbGeAlD
Doxorubicin—XDH—renal system—colon cancer	0.000185	0.00615	CbGeAlD
Doxorubicin—ABCB8—lymph node—colon cancer	0.000185	0.00613	CbGeAlD
Doxorubicin—NDUFS2—lymphoid tissue—colon cancer	0.000183	0.00608	CbGeAlD
Doxorubicin—NOS1—digestive system—colon cancer	0.000182	0.00604	CbGeAlD
Doxorubicin—NOS3—epithelium—colon cancer	0.000182	0.00604	CbGeAlD
Doxorubicin—NDUFS2—digestive system—colon cancer	0.000181	0.006	CbGeAlD
Doxorubicin—NDUFS3—lymphoid tissue—colon cancer	0.000181	0.006	CbGeAlD
Doxorubicin—AURKA—vagina—colon cancer	0.000179	0.00595	CbGeAlD
Doxorubicin—AKR1A1—liver—colon cancer	0.000179	0.00594	CbGeAlD
Doxorubicin—NDUFS3—digestive system—colon cancer	0.000179	0.00593	CbGeAlD
Doxorubicin—RALBP1—smooth muscle tissue—colon cancer	0.000178	0.00591	CbGeAlD
Doxorubicin—CBR3—lymph node—colon cancer	0.000178	0.0059	CbGeAlD
Doxorubicin—NOS3—smooth muscle tissue—colon cancer	0.000175	0.00582	CbGeAlD
Doxorubicin—DHCR7—lymphoid tissue—colon cancer	0.000172	0.0057	CbGeAlD
Doxorubicin—RALBP1—renal system—colon cancer	0.000171	0.00569	CbGeAlD
Doxorubicin—DHCR7—digestive system—colon cancer	0.00017	0.00563	CbGeAlD
Doxorubicin—NOS3—renal system—colon cancer	0.000169	0.0056	CbGeAlD
Doxorubicin—NDUFS2—bone marrow—colon cancer	0.000167	0.00553	CbGeAlD
Doxorubicin—NDUFS3—bone marrow—colon cancer	0.000165	0.00547	CbGeAlD
Doxorubicin—AKR1C3—smooth muscle tissue—colon cancer	0.000164	0.00545	CbGeAlD
Doxorubicin—NDUFS7—liver—colon cancer	0.000163	0.0054	CbGeAlD
Doxorubicin—CBR1—renal system—colon cancer	0.00016	0.00531	CbGeAlD
Doxorubicin—NDUFS2—vagina—colon cancer	0.00016	0.0053	CbGeAlD
Doxorubicin—NDUFS3—vagina—colon cancer	0.000158	0.00524	CbGeAlD
Doxorubicin—YWHAG—lymphoid tissue—colon cancer	0.000158	0.00523	CbGeAlD
Doxorubicin—DHCR7—bone marrow—colon cancer	0.000156	0.00519	CbGeAlD
Doxorubicin—YWHAG—digestive system—colon cancer	0.000156	0.00517	CbGeAlD
Doxorubicin—XDH—digestive system—colon cancer	0.000152	0.00504	CbGeAlD
Doxorubicin—AURKA—liver—colon cancer	0.000151	0.00502	CbGeAlD
Doxorubicin—DHCR7—vagina—colon cancer	0.00015	0.00498	CbGeAlD
Doxorubicin—ABCB11—digestive system—colon cancer	0.000148	0.00493	CbGeAlD
Doxorubicin—TOP2A—Topotecan—Irinotecan—colon cancer	0.000147	0.152	CbGdCrCtD
Doxorubicin—YWHAG—bone marrow—colon cancer	0.000144	0.00477	CbGeAlD
Doxorubicin—RALBP1—digestive system—colon cancer	0.000141	0.00467	CbGeAlD
Doxorubicin—NOS3—lymphoid tissue—colon cancer	0.00014	0.00465	CbGeAlD
Doxorubicin—NOS3—digestive system—colon cancer	0.000138	0.00459	CbGeAlD
Doxorubicin—NQO1—epithelium—colon cancer	0.000138	0.00459	CbGeAlD
Doxorubicin—YWHAG—vagina—colon cancer	0.000138	0.00457	CbGeAlD
Doxorubicin—AKR1A1—lymph node—colon cancer	0.000137	0.00455	CbGeAlD
Doxorubicin—NDUFS2—liver—colon cancer	0.000135	0.00447	CbGeAlD
Doxorubicin—XDH—vagina—colon cancer	0.000134	0.00445	CbGeAlD
Doxorubicin—NQO1—smooth muscle tissue—colon cancer	0.000133	0.00442	CbGeAlD
Doxorubicin—NDUFS3—liver—colon cancer	0.000133	0.00442	CbGeAlD
Doxorubicin—CBR1—lymphoid tissue—colon cancer	0.000133	0.00441	CbGeAlD
Doxorubicin—CBR1—digestive system—colon cancer	0.000131	0.00436	CbGeAlD
Doxorubicin—RALBP1—bone marrow—colon cancer	0.00013	0.0043	CbGeAlD
Doxorubicin—NQO1—renal system—colon cancer	0.000128	0.00426	CbGeAlD
Doxorubicin—DHCR7—liver—colon cancer	0.000126	0.0042	CbGeAlD
Doxorubicin—NDUFS7—lymph node—colon cancer	0.000125	0.00414	CbGeAlD
Doxorubicin—RALBP1—vagina—colon cancer	0.000124	0.00412	CbGeAlD
Doxorubicin—ABCC6—liver—colon cancer	0.000123	0.00409	CbGeAlD
Doxorubicin—NOS3—vagina—colon cancer	0.000122	0.00406	CbGeAlD
Doxorubicin—CBR1—bone marrow—colon cancer	0.000121	0.00402	CbGeAlD
Doxorubicin—AKR1C3—bone marrow—colon cancer	0.00012	0.00397	CbGeAlD
Doxorubicin—YWHAG—liver—colon cancer	0.000116	0.00385	CbGeAlD
Doxorubicin—CBR1—vagina—colon cancer	0.000116	0.00385	CbGeAlD
Doxorubicin—AURKA—lymph node—colon cancer	0.000116	0.00385	CbGeAlD
Doxorubicin—ABCC3—renal system—colon cancer	0.000115	0.00382	CbGeAlD
Doxorubicin—ABCC10—renal system—colon cancer	0.000115	0.0038	CbGeAlD
Doxorubicin—AKR1C3—vagina—colon cancer	0.000115	0.0038	CbGeAlD
Doxorubicin—XDH—liver—colon cancer	0.000113	0.00376	CbGeAlD
Doxorubicin—ABCB11—liver—colon cancer	0.000111	0.00367	CbGeAlD
Doxorubicin—POR—bone marrow—colon cancer	0.000109	0.00362	CbGeAlD
Doxorubicin—NQO1—digestive system—colon cancer	0.000105	0.00349	CbGeAlD
Doxorubicin—TOP2A—Vindesine—Vincristine—colon cancer	0.000105	0.108	CbGdCrCtD
Doxorubicin—RALBP1—liver—colon cancer	0.000105	0.00348	CbGeAlD
Doxorubicin—POR—vagina—colon cancer	0.000105	0.00347	CbGeAlD
Doxorubicin—NDUFS2—lymph node—colon cancer	0.000103	0.00343	CbGeAlD
Doxorubicin—NOS3—liver—colon cancer	0.000103	0.00342	CbGeAlD
Doxorubicin—NDUFS3—lymph node—colon cancer	0.000102	0.00339	CbGeAlD
Doxorubicin—TOP2A—bone marrow—colon cancer	0.000102	0.00338	CbGeAlD
Doxorubicin—CBR1—liver—colon cancer	9.78e-05	0.00325	CbGeAlD
Doxorubicin—TOP2A—vagina—colon cancer	9.75e-05	0.00324	CbGeAlD
Doxorubicin—DHCR7—lymph node—colon cancer	9.69e-05	0.00322	CbGeAlD
Doxorubicin—AKR1C3—liver—colon cancer	9.66e-05	0.00321	CbGeAlD
Doxorubicin—ABCC10—lymphoid tissue—colon cancer	9.51e-05	0.00316	CbGeAlD
Doxorubicin—ABCC3—digestive system—colon cancer	9.44e-05	0.00313	CbGeAlD
Doxorubicin—ABCC10—digestive system—colon cancer	9.4e-05	0.00312	CbGeAlD
Doxorubicin—CYP1B1—smooth muscle tissue—colon cancer	9.36e-05	0.00311	CbGeAlD
Doxorubicin—NQO1—vagina—colon cancer	9.29e-05	0.00308	CbGeAlD
Doxorubicin—ABCC2—renal system—colon cancer	9.2e-05	0.00305	CbGeAlD
Doxorubicin—CYP1B1—renal system—colon cancer	9.01e-05	0.00299	CbGeAlD
Doxorubicin—YWHAG—lymph node—colon cancer	8.9e-05	0.00295	CbGeAlD
Doxorubicin—POR—liver—colon cancer	8.82e-05	0.00293	CbGeAlD
Doxorubicin—ABCC10—bone marrow—colon cancer	8.66e-05	0.00288	CbGeAlD
Doxorubicin—ABCC10—vagina—colon cancer	8.3e-05	0.00275	CbGeAlD
Doxorubicin—RALBP1—lymph node—colon cancer	8.03e-05	0.00267	CbGeAlD
Doxorubicin—NOS3—lymph node—colon cancer	7.9e-05	0.00262	CbGeAlD
Doxorubicin—NQO1—liver—colon cancer	7.84e-05	0.0026	CbGeAlD
Doxorubicin—ABCC2—digestive system—colon cancer	7.54e-05	0.0025	CbGeAlD
Doxorubicin—CBR1—lymph node—colon cancer	7.5e-05	0.00249	CbGeAlD
Doxorubicin—CYP1B1—lymphoid tissue—colon cancer	7.48e-05	0.00248	CbGeAlD
Doxorubicin—AKR1C3—lymph node—colon cancer	7.41e-05	0.00246	CbGeAlD
Doxorubicin—CYP1B1—digestive system—colon cancer	7.39e-05	0.00245	CbGeAlD
Doxorubicin—ABCB1—blood vessel—colon cancer	7.33e-05	0.00243	CbGeAlD
Doxorubicin—ABCC3—liver—colon cancer	7.03e-05	0.00234	CbGeAlD
Doxorubicin—ABCC10—liver—colon cancer	7e-05	0.00232	CbGeAlD
Doxorubicin—POR—lymph node—colon cancer	6.76e-05	0.00225	CbGeAlD
Doxorubicin—TOP2A—Vinorelbine—Vincristine—colon cancer	6.63e-05	0.0685	CbGdCrCtD
Doxorubicin—TOP2A—lymph node—colon cancer	6.3e-05	0.00209	CbGeAlD
Doxorubicin—CYP2B6—renal system—colon cancer	6.19e-05	0.00205	CbGeAlD
Doxorubicin—NQO1—lymph node—colon cancer	6.01e-05	0.00199	CbGeAlD
Doxorubicin—ABCC1—vagina—colon cancer	5.87e-05	0.00195	CbGeAlD
Doxorubicin—ABCC2—liver—colon cancer	5.62e-05	0.00187	CbGeAlD
Doxorubicin—CYP1B1—liver—colon cancer	5.5e-05	0.00183	CbGeAlD
Doxorubicin—ABCC3—lymph node—colon cancer	5.39e-05	0.00179	CbGeAlD
Doxorubicin—ABCC10—lymph node—colon cancer	5.37e-05	0.00178	CbGeAlD
Doxorubicin—CYP2B6—lymphoid tissue—colon cancer	5.14e-05	0.00171	CbGeAlD
Doxorubicin—CYP2B6—digestive system—colon cancer	5.08e-05	0.00168	CbGeAlD
Doxorubicin—ABCG2—bone marrow—colon cancer	5.07e-05	0.00168	CbGeAlD
Doxorubicin—ABCC1—liver—colon cancer	4.95e-05	0.00164	CbGeAlD
Doxorubicin—ABCG2—vagina—colon cancer	4.86e-05	0.00161	CbGeAlD
Doxorubicin—CYP3A4—renal system—colon cancer	4.67e-05	0.00155	CbGeAlD
Doxorubicin—CYP2D6—renal system—colon cancer	4.6e-05	0.00153	CbGeAlD
Doxorubicin—TOP2A—Vinblastine—Vincristine—colon cancer	4.56e-05	0.0471	CbGdCrCtD
Doxorubicin—CYP2B6—vagina—colon cancer	4.48e-05	0.00149	CbGeAlD
Doxorubicin—ABCB1—embryo—colon cancer	4.37e-05	0.00145	CbGeAlD
Doxorubicin—ABCC2—lymph node—colon cancer	4.31e-05	0.00143	CbGeAlD
Doxorubicin—CYP1B1—lymph node—colon cancer	4.22e-05	0.0014	CbGeAlD
Doxorubicin—ABCG2—liver—colon cancer	4.1e-05	0.00136	CbGeAlD
Doxorubicin—CYP3A4—digestive system—colon cancer	3.83e-05	0.00127	CbGeAlD
Doxorubicin—ABCC1—lymph node—colon cancer	3.8e-05	0.00126	CbGeAlD
Doxorubicin—CYP2B6—liver—colon cancer	3.78e-05	0.00126	CbGeAlD
Doxorubicin—CYP2D6—digestive system—colon cancer	3.77e-05	0.00125	CbGeAlD
Doxorubicin—ABCB1—epithelium—colon cancer	3.57e-05	0.00118	CbGeAlD
Doxorubicin—ABCB1—renal system—colon cancer	3.31e-05	0.0011	CbGeAlD
Doxorubicin—ABCG2—lymph node—colon cancer	3.14e-05	0.00104	CbGeAlD
Doxorubicin—CYP3A4—liver—colon cancer	2.86e-05	0.000948	CbGeAlD
Doxorubicin—CYP2D6—liver—colon cancer	2.81e-05	0.000933	CbGeAlD
Doxorubicin—Anaphylactic shock—Fluorouracil—colon cancer	2.77e-05	0.000573	CcSEcCtD
Doxorubicin—Oedema—Fluorouracil—colon cancer	2.77e-05	0.000573	CcSEcCtD
Doxorubicin—Anorexia—Irinotecan—colon cancer	2.76e-05	0.00057	CcSEcCtD
Doxorubicin—Ataxia—Methotrexate—colon cancer	2.76e-05	0.00057	CcSEcCtD
Doxorubicin—Infection—Fluorouracil—colon cancer	2.75e-05	0.000569	CcSEcCtD
Doxorubicin—ABCB1—lymphoid tissue—colon cancer	2.75e-05	0.000912	CbGeAlD
Doxorubicin—Haemoglobin—Capecitabine—colon cancer	2.74e-05	0.000567	CcSEcCtD
Doxorubicin—Rhinitis—Capecitabine—colon cancer	2.73e-05	0.000565	CcSEcCtD
Doxorubicin—Haemorrhage—Capecitabine—colon cancer	2.72e-05	0.000564	CcSEcCtD
Doxorubicin—Hepatitis—Capecitabine—colon cancer	2.72e-05	0.000564	CcSEcCtD
Doxorubicin—Nervous system disorder—Fluorouracil—colon cancer	2.72e-05	0.000562	CcSEcCtD
Doxorubicin—ABCB1—digestive system—colon cancer	2.71e-05	0.000901	CbGeAlD
Doxorubicin—Thrombocytopenia—Fluorouracil—colon cancer	2.71e-05	0.000561	CcSEcCtD
Doxorubicin—Hypoaesthesia—Capecitabine—colon cancer	2.71e-05	0.000561	CcSEcCtD
Doxorubicin—Liver function test abnormal—Methotrexate—colon cancer	2.71e-05	0.00056	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Vincristine—colon cancer	2.7e-05	0.00056	CcSEcCtD
Doxorubicin—Pharyngitis—Capecitabine—colon cancer	2.7e-05	0.00056	CcSEcCtD
Doxorubicin—Tachycardia—Fluorouracil—colon cancer	2.7e-05	0.000559	CcSEcCtD
Doxorubicin—Hypotension—Irinotecan—colon cancer	2.7e-05	0.000559	CcSEcCtD
Doxorubicin—Urinary tract disorder—Capecitabine—colon cancer	2.69e-05	0.000557	CcSEcCtD
Doxorubicin—Insomnia—Vincristine—colon cancer	2.68e-05	0.000556	CcSEcCtD
Doxorubicin—Oedema peripheral—Capecitabine—colon cancer	2.68e-05	0.000555	CcSEcCtD
Doxorubicin—Connective tissue disorder—Capecitabine—colon cancer	2.68e-05	0.000554	CcSEcCtD
Doxorubicin—Urethral disorder—Capecitabine—colon cancer	2.67e-05	0.000553	CcSEcCtD
Doxorubicin—Paraesthesia—Vincristine—colon cancer	2.67e-05	0.000552	CcSEcCtD
Doxorubicin—Breast disorder—Methotrexate—colon cancer	2.65e-05	0.000548	CcSEcCtD
Doxorubicin—Anorexia—Fluorouracil—colon cancer	2.64e-05	0.000546	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Methotrexate—colon cancer	2.64e-05	0.000546	CcSEcCtD
Doxorubicin—Visual impairment—Capecitabine—colon cancer	2.62e-05	0.000543	CcSEcCtD
Doxorubicin—Insomnia—Irinotecan—colon cancer	2.61e-05	0.000541	CcSEcCtD
Doxorubicin—Paraesthesia—Irinotecan—colon cancer	2.6e-05	0.000537	CcSEcCtD
Doxorubicin—Hypotension—Fluorouracil—colon cancer	2.59e-05	0.000536	CcSEcCtD
Doxorubicin—Decreased appetite—Vincristine—colon cancer	2.58e-05	0.000534	CcSEcCtD
Doxorubicin—Dyspnoea—Irinotecan—colon cancer	2.58e-05	0.000534	CcSEcCtD
Doxorubicin—Erythema multiforme—Capecitabine—colon cancer	2.58e-05	0.000533	CcSEcCtD
Doxorubicin—Somnolence—Irinotecan—colon cancer	2.57e-05	0.000532	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Vincristine—colon cancer	2.56e-05	0.000531	CcSEcCtD
Doxorubicin—Fatigue—Vincristine—colon cancer	2.56e-05	0.00053	CcSEcCtD
Doxorubicin—Eye disorder—Capecitabine—colon cancer	2.55e-05	0.000527	CcSEcCtD
Doxorubicin—Dyspepsia—Irinotecan—colon cancer	2.54e-05	0.000527	CcSEcCtD
Doxorubicin—Tinnitus—Capecitabine—colon cancer	2.54e-05	0.000526	CcSEcCtD
Doxorubicin—Constipation—Vincristine—colon cancer	2.54e-05	0.000526	CcSEcCtD
Doxorubicin—Pain—Vincristine—colon cancer	2.54e-05	0.000526	CcSEcCtD
Doxorubicin—Asthma—Methotrexate—colon cancer	2.53e-05	0.000524	CcSEcCtD
Doxorubicin—Flushing—Capecitabine—colon cancer	2.53e-05	0.000523	CcSEcCtD
Doxorubicin—Cardiac disorder—Capecitabine—colon cancer	2.53e-05	0.000523	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Fluorouracil—colon cancer	2.52e-05	0.000522	CcSEcCtD
Doxorubicin—Decreased appetite—Irinotecan—colon cancer	2.51e-05	0.00052	CcSEcCtD
Doxorubicin—Eosinophilia—Methotrexate—colon cancer	2.51e-05	0.000519	CcSEcCtD
Doxorubicin—Insomnia—Fluorouracil—colon cancer	2.5e-05	0.000518	CcSEcCtD
Doxorubicin—ABCB1—bone marrow—colon cancer	2.5e-05	0.00083	CbGeAlD
Doxorubicin—Gastrointestinal disorder—Irinotecan—colon cancer	2.5e-05	0.000517	CcSEcCtD
Doxorubicin—Fatigue—Irinotecan—colon cancer	2.49e-05	0.000516	CcSEcCtD
Doxorubicin—Paraesthesia—Fluorouracil—colon cancer	2.49e-05	0.000515	CcSEcCtD
Doxorubicin—Pancreatitis—Methotrexate—colon cancer	2.48e-05	0.000514	CcSEcCtD
Doxorubicin—Pain—Irinotecan—colon cancer	2.47e-05	0.000512	CcSEcCtD
Doxorubicin—Constipation—Irinotecan—colon cancer	2.47e-05	0.000512	CcSEcCtD
Doxorubicin—Angiopathy—Capecitabine—colon cancer	2.47e-05	0.000512	CcSEcCtD
Doxorubicin—Dyspnoea—Fluorouracil—colon cancer	2.47e-05	0.000511	CcSEcCtD
Doxorubicin—Somnolence—Fluorouracil—colon cancer	2.46e-05	0.00051	CcSEcCtD
Doxorubicin—Immune system disorder—Capecitabine—colon cancer	2.46e-05	0.000509	CcSEcCtD
Doxorubicin—Mediastinal disorder—Capecitabine—colon cancer	2.45e-05	0.000508	CcSEcCtD
Doxorubicin—Chills—Capecitabine—colon cancer	2.44e-05	0.000506	CcSEcCtD
Doxorubicin—Dyspepsia—Fluorouracil—colon cancer	2.44e-05	0.000505	CcSEcCtD
Doxorubicin—Arrhythmia—Capecitabine—colon cancer	2.43e-05	0.000504	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Vincristine—colon cancer	2.43e-05	0.000503	CcSEcCtD
Doxorubicin—Decreased appetite—Fluorouracil—colon cancer	2.41e-05	0.000498	CcSEcCtD
Doxorubicin—Alopecia—Capecitabine—colon cancer	2.41e-05	0.000498	CcSEcCtD
Doxorubicin—Pancytopenia—Methotrexate—colon cancer	2.41e-05	0.000498	CcSEcCtD
Doxorubicin—ABCB1—vagina—colon cancer	2.4e-05	0.000795	CbGeAlD
Doxorubicin—Gastrointestinal disorder—Fluorouracil—colon cancer	2.39e-05	0.000495	CcSEcCtD
Doxorubicin—Mental disorder—Capecitabine—colon cancer	2.39e-05	0.000494	CcSEcCtD
Doxorubicin—Feeling abnormal—Irinotecan—colon cancer	2.38e-05	0.000493	CcSEcCtD
Doxorubicin—Erythema—Capecitabine—colon cancer	2.37e-05	0.000491	CcSEcCtD
Doxorubicin—Malnutrition—Capecitabine—colon cancer	2.37e-05	0.000491	CcSEcCtD
Doxorubicin—Dysuria—Methotrexate—colon cancer	2.37e-05	0.00049	CcSEcCtD
Doxorubicin—Neutropenia—Methotrexate—colon cancer	2.37e-05	0.00049	CcSEcCtD
Doxorubicin—Pain—Fluorouracil—colon cancer	2.37e-05	0.00049	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Irinotecan—colon cancer	2.36e-05	0.000489	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Methotrexate—colon cancer	2.35e-05	0.000487	CcSEcCtD
Doxorubicin—Abdominal pain—Vincristine—colon cancer	2.35e-05	0.000486	CcSEcCtD
Doxorubicin—Body temperature increased—Vincristine—colon cancer	2.35e-05	0.000486	CcSEcCtD
Doxorubicin—Flatulence—Capecitabine—colon cancer	2.34e-05	0.000484	CcSEcCtD
Doxorubicin—Dysgeusia—Capecitabine—colon cancer	2.32e-05	0.000481	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Methotrexate—colon cancer	2.31e-05	0.000479	CcSEcCtD
Doxorubicin—Back pain—Capecitabine—colon cancer	2.29e-05	0.000475	CcSEcCtD
Doxorubicin—Body temperature increased—Irinotecan—colon cancer	2.29e-05	0.000473	CcSEcCtD
Doxorubicin—Abdominal pain—Irinotecan—colon cancer	2.29e-05	0.000473	CcSEcCtD
Doxorubicin—Feeling abnormal—Fluorouracil—colon cancer	2.28e-05	0.000472	CcSEcCtD
Doxorubicin—Muscle spasms—Capecitabine—colon cancer	2.28e-05	0.000472	CcSEcCtD
Doxorubicin—Pneumonia—Methotrexate—colon cancer	2.27e-05	0.00047	CcSEcCtD
Doxorubicin—Infestation—Methotrexate—colon cancer	2.26e-05	0.000468	CcSEcCtD
Doxorubicin—Drowsiness—Methotrexate—colon cancer	2.26e-05	0.000468	CcSEcCtD
Doxorubicin—Infestation NOS—Methotrexate—colon cancer	2.26e-05	0.000468	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Methotrexate—colon cancer	2.24e-05	0.000464	CcSEcCtD
Doxorubicin—Vision blurred—Capecitabine—colon cancer	2.23e-05	0.000463	CcSEcCtD
Doxorubicin—Renal failure—Methotrexate—colon cancer	2.22e-05	0.00046	CcSEcCtD
Doxorubicin—Stomatitis—Methotrexate—colon cancer	2.2e-05	0.000456	CcSEcCtD
Doxorubicin—Ill-defined disorder—Capecitabine—colon cancer	2.2e-05	0.000455	CcSEcCtD
Doxorubicin—Urticaria—Fluorouracil—colon cancer	2.2e-05	0.000455	CcSEcCtD
Doxorubicin—Conjunctivitis—Methotrexate—colon cancer	2.2e-05	0.000454	CcSEcCtD
Doxorubicin—Anaemia—Capecitabine—colon cancer	2.19e-05	0.000454	CcSEcCtD
Doxorubicin—Body temperature increased—Fluorouracil—colon cancer	2.19e-05	0.000453	CcSEcCtD
Doxorubicin—Hypersensitivity—Vincristine—colon cancer	2.19e-05	0.000453	CcSEcCtD
Doxorubicin—Sweating—Methotrexate—colon cancer	2.17e-05	0.000448	CcSEcCtD
Doxorubicin—Haematuria—Methotrexate—colon cancer	2.15e-05	0.000446	CcSEcCtD
Doxorubicin—Malaise—Capecitabine—colon cancer	2.14e-05	0.000443	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Methotrexate—colon cancer	2.14e-05	0.000442	CcSEcCtD
Doxorubicin—Epistaxis—Methotrexate—colon cancer	2.13e-05	0.000441	CcSEcCtD
Doxorubicin—Vertigo—Capecitabine—colon cancer	2.13e-05	0.000441	CcSEcCtD
Doxorubicin—Hypersensitivity—Irinotecan—colon cancer	2.13e-05	0.000441	CcSEcCtD
Doxorubicin—Asthenia—Vincristine—colon cancer	2.13e-05	0.000441	CcSEcCtD
Doxorubicin—Syncope—Capecitabine—colon cancer	2.13e-05	0.00044	CcSEcCtD
Doxorubicin—Leukopenia—Capecitabine—colon cancer	2.12e-05	0.000439	CcSEcCtD
Doxorubicin—Agranulocytosis—Methotrexate—colon cancer	2.11e-05	0.000436	CcSEcCtD
Doxorubicin—Palpitations—Capecitabine—colon cancer	2.1e-05	0.000434	CcSEcCtD
Doxorubicin—Loss of consciousness—Capecitabine—colon cancer	2.08e-05	0.000431	CcSEcCtD
Doxorubicin—Asthenia—Irinotecan—colon cancer	2.07e-05	0.000429	CcSEcCtD
Doxorubicin—Cough—Capecitabine—colon cancer	2.07e-05	0.000428	CcSEcCtD
Doxorubicin—Hypertension—Capecitabine—colon cancer	2.05e-05	0.000424	CcSEcCtD
Doxorubicin—Hypersensitivity—Fluorouracil—colon cancer	2.04e-05	0.000422	CcSEcCtD
Doxorubicin—Haemoglobin—Methotrexate—colon cancer	2.04e-05	0.000422	CcSEcCtD
Doxorubicin—Diarrhoea—Vincristine—colon cancer	2.03e-05	0.00042	CcSEcCtD
Doxorubicin—Haemorrhage—Methotrexate—colon cancer	2.03e-05	0.00042	CcSEcCtD
Doxorubicin—Hepatitis—Methotrexate—colon cancer	2.03e-05	0.00042	CcSEcCtD
Doxorubicin—ABCB1—liver—colon cancer	2.02e-05	0.000671	CbGeAlD
Doxorubicin—Arthralgia—Capecitabine—colon cancer	2.02e-05	0.000418	CcSEcCtD
Doxorubicin—Myalgia—Capecitabine—colon cancer	2.02e-05	0.000418	CcSEcCtD
Doxorubicin—Chest pain—Capecitabine—colon cancer	2.02e-05	0.000418	CcSEcCtD
Doxorubicin—Pharyngitis—Methotrexate—colon cancer	2.01e-05	0.000417	CcSEcCtD
Doxorubicin—Anxiety—Capecitabine—colon cancer	2.01e-05	0.000416	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	2e-05	0.000415	CcSEcCtD
Doxorubicin—Urinary tract disorder—Methotrexate—colon cancer	2e-05	0.000414	CcSEcCtD
Doxorubicin—Discomfort—Capecitabine—colon cancer	1.99e-05	0.000413	CcSEcCtD
Doxorubicin—Urethral disorder—Methotrexate—colon cancer	1.99e-05	0.000411	CcSEcCtD
Doxorubicin—Diarrhoea—Irinotecan—colon cancer	1.98e-05	0.000409	CcSEcCtD
Doxorubicin—Dry mouth—Capecitabine—colon cancer	1.97e-05	0.000409	CcSEcCtD
Doxorubicin—Dizziness—Vincristine—colon cancer	1.96e-05	0.000406	CcSEcCtD
Doxorubicin—Pruritus—Fluorouracil—colon cancer	1.96e-05	0.000406	CcSEcCtD
Doxorubicin—Visual impairment—Methotrexate—colon cancer	1.95e-05	0.000404	CcSEcCtD
Doxorubicin—Confusional state—Capecitabine—colon cancer	1.95e-05	0.000404	CcSEcCtD
Doxorubicin—Oedema—Capecitabine—colon cancer	1.93e-05	0.000401	CcSEcCtD
Doxorubicin—Infection—Capecitabine—colon cancer	1.92e-05	0.000398	CcSEcCtD
Doxorubicin—Erythema multiforme—Methotrexate—colon cancer	1.92e-05	0.000397	CcSEcCtD
Doxorubicin—Dizziness—Irinotecan—colon cancer	1.91e-05	0.000396	CcSEcCtD
Doxorubicin—Shock—Capecitabine—colon cancer	1.9e-05	0.000394	CcSEcCtD
Doxorubicin—Nervous system disorder—Capecitabine—colon cancer	1.9e-05	0.000393	CcSEcCtD
Doxorubicin—Eye disorder—Methotrexate—colon cancer	1.89e-05	0.000392	CcSEcCtD
Doxorubicin—Diarrhoea—Fluorouracil—colon cancer	1.89e-05	0.000392	CcSEcCtD
Doxorubicin—Thrombocytopenia—Capecitabine—colon cancer	1.89e-05	0.000392	CcSEcCtD
Doxorubicin—Tinnitus—Methotrexate—colon cancer	1.89e-05	0.000391	CcSEcCtD
Doxorubicin—Tachycardia—Capecitabine—colon cancer	1.89e-05	0.000391	CcSEcCtD
Doxorubicin—Vomiting—Vincristine—colon cancer	1.89e-05	0.000391	CcSEcCtD
Doxorubicin—Cardiac disorder—Methotrexate—colon cancer	1.88e-05	0.00039	CcSEcCtD
Doxorubicin—Skin disorder—Capecitabine—colon cancer	1.88e-05	0.000389	CcSEcCtD
Doxorubicin—Rash—Vincristine—colon cancer	1.87e-05	0.000387	CcSEcCtD
Doxorubicin—Hyperhidrosis—Capecitabine—colon cancer	1.87e-05	0.000387	CcSEcCtD
Doxorubicin—Dermatitis—Vincristine—colon cancer	1.87e-05	0.000387	CcSEcCtD
Doxorubicin—Headache—Vincristine—colon cancer	1.86e-05	0.000385	CcSEcCtD
Doxorubicin—Anorexia—Capecitabine—colon cancer	1.84e-05	0.000382	CcSEcCtD
Doxorubicin—Angiopathy—Methotrexate—colon cancer	1.84e-05	0.000381	CcSEcCtD
Doxorubicin—Vomiting—Irinotecan—colon cancer	1.84e-05	0.000381	CcSEcCtD
Doxorubicin—Immune system disorder—Methotrexate—colon cancer	1.83e-05	0.000379	CcSEcCtD
Doxorubicin—Dizziness—Fluorouracil—colon cancer	1.83e-05	0.000379	CcSEcCtD
Doxorubicin—Mediastinal disorder—Methotrexate—colon cancer	1.83e-05	0.000378	CcSEcCtD
Doxorubicin—Rash—Irinotecan—colon cancer	1.82e-05	0.000377	CcSEcCtD
Doxorubicin—Dermatitis—Irinotecan—colon cancer	1.82e-05	0.000377	CcSEcCtD
Doxorubicin—Chills—Methotrexate—colon cancer	1.82e-05	0.000377	CcSEcCtD
Doxorubicin—Headache—Irinotecan—colon cancer	1.81e-05	0.000375	CcSEcCtD
Doxorubicin—Hypotension—Capecitabine—colon cancer	1.81e-05	0.000374	CcSEcCtD
Doxorubicin—Alopecia—Methotrexate—colon cancer	1.79e-05	0.000371	CcSEcCtD
Doxorubicin—Mental disorder—Methotrexate—colon cancer	1.78e-05	0.000368	CcSEcCtD
Doxorubicin—Erythema—Methotrexate—colon cancer	1.76e-05	0.000365	CcSEcCtD
Doxorubicin—Malnutrition—Methotrexate—colon cancer	1.76e-05	0.000365	CcSEcCtD
Doxorubicin—Nausea—Vincristine—colon cancer	1.76e-05	0.000365	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Capecitabine—colon cancer	1.76e-05	0.000365	CcSEcCtD
Doxorubicin—Vomiting—Fluorouracil—colon cancer	1.76e-05	0.000364	CcSEcCtD
Doxorubicin—Insomnia—Capecitabine—colon cancer	1.75e-05	0.000362	CcSEcCtD
Doxorubicin—Rash—Fluorouracil—colon cancer	1.75e-05	0.000361	CcSEcCtD
Doxorubicin—Dermatitis—Fluorouracil—colon cancer	1.74e-05	0.000361	CcSEcCtD
Doxorubicin—Paraesthesia—Capecitabine—colon cancer	1.74e-05	0.00036	CcSEcCtD
Doxorubicin—Headache—Fluorouracil—colon cancer	1.73e-05	0.000359	CcSEcCtD
Doxorubicin—Dysgeusia—Methotrexate—colon cancer	1.73e-05	0.000358	CcSEcCtD
Doxorubicin—Dyspnoea—Capecitabine—colon cancer	1.73e-05	0.000357	CcSEcCtD
Doxorubicin—Nausea—Irinotecan—colon cancer	1.72e-05	0.000355	CcSEcCtD
Doxorubicin—Back pain—Methotrexate—colon cancer	1.71e-05	0.000353	CcSEcCtD
Doxorubicin—Dyspepsia—Capecitabine—colon cancer	1.7e-05	0.000353	CcSEcCtD
Doxorubicin—Decreased appetite—Capecitabine—colon cancer	1.68e-05	0.000348	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Capecitabine—colon cancer	1.67e-05	0.000346	CcSEcCtD
Doxorubicin—Fatigue—Capecitabine—colon cancer	1.67e-05	0.000345	CcSEcCtD
Doxorubicin—Vision blurred—Methotrexate—colon cancer	1.66e-05	0.000344	CcSEcCtD
Doxorubicin—Constipation—Capecitabine—colon cancer	1.65e-05	0.000343	CcSEcCtD
Doxorubicin—Pain—Capecitabine—colon cancer	1.65e-05	0.000343	CcSEcCtD
Doxorubicin—Nausea—Fluorouracil—colon cancer	1.64e-05	0.00034	CcSEcCtD
Doxorubicin—Ill-defined disorder—Methotrexate—colon cancer	1.64e-05	0.000339	CcSEcCtD
Doxorubicin—Anaemia—Methotrexate—colon cancer	1.63e-05	0.000338	CcSEcCtD
Doxorubicin—Feeling abnormal—Capecitabine—colon cancer	1.59e-05	0.00033	CcSEcCtD
Doxorubicin—Malaise—Methotrexate—colon cancer	1.59e-05	0.000329	CcSEcCtD
Doxorubicin—Vertigo—Methotrexate—colon cancer	1.59e-05	0.000328	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Capecitabine—colon cancer	1.58e-05	0.000328	CcSEcCtD
Doxorubicin—Leukopenia—Methotrexate—colon cancer	1.58e-05	0.000327	CcSEcCtD
Doxorubicin—ABCB1—lymph node—colon cancer	1.55e-05	0.000514	CbGeAlD
Doxorubicin—Cough—Methotrexate—colon cancer	1.54e-05	0.000319	CcSEcCtD
Doxorubicin—Urticaria—Capecitabine—colon cancer	1.54e-05	0.000318	CcSEcCtD
Doxorubicin—Abdominal pain—Capecitabine—colon cancer	1.53e-05	0.000317	CcSEcCtD
Doxorubicin—Body temperature increased—Capecitabine—colon cancer	1.53e-05	0.000317	CcSEcCtD
Doxorubicin—Convulsion—Methotrexate—colon cancer	1.53e-05	0.000317	CcSEcCtD
Doxorubicin—Chest pain—Methotrexate—colon cancer	1.5e-05	0.000311	CcSEcCtD
Doxorubicin—Arthralgia—Methotrexate—colon cancer	1.5e-05	0.000311	CcSEcCtD
Doxorubicin—Myalgia—Methotrexate—colon cancer	1.5e-05	0.000311	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	1.49e-05	0.000309	CcSEcCtD
Doxorubicin—Discomfort—Methotrexate—colon cancer	1.48e-05	0.000307	CcSEcCtD
Doxorubicin—Confusional state—Methotrexate—colon cancer	1.45e-05	0.000301	CcSEcCtD
Doxorubicin—Anaphylactic shock—Methotrexate—colon cancer	1.44e-05	0.000298	CcSEcCtD
Doxorubicin—Infection—Methotrexate—colon cancer	1.43e-05	0.000296	CcSEcCtD
Doxorubicin—Hypersensitivity—Capecitabine—colon cancer	1.43e-05	0.000295	CcSEcCtD
Doxorubicin—Nervous system disorder—Methotrexate—colon cancer	1.41e-05	0.000292	CcSEcCtD
Doxorubicin—Thrombocytopenia—Methotrexate—colon cancer	1.41e-05	0.000292	CcSEcCtD
Doxorubicin—Skin disorder—Methotrexate—colon cancer	1.4e-05	0.00029	CcSEcCtD
Doxorubicin—Hyperhidrosis—Methotrexate—colon cancer	1.39e-05	0.000288	CcSEcCtD
Doxorubicin—Asthenia—Capecitabine—colon cancer	1.39e-05	0.000287	CcSEcCtD
Doxorubicin—Anorexia—Methotrexate—colon cancer	1.37e-05	0.000284	CcSEcCtD
Doxorubicin—Pruritus—Capecitabine—colon cancer	1.37e-05	0.000283	CcSEcCtD
Doxorubicin—Hypotension—Methotrexate—colon cancer	1.35e-05	0.000279	CcSEcCtD
Doxorubicin—Diarrhoea—Capecitabine—colon cancer	1.32e-05	0.000274	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Methotrexate—colon cancer	1.31e-05	0.000272	CcSEcCtD
Doxorubicin—Insomnia—Methotrexate—colon cancer	1.3e-05	0.00027	CcSEcCtD
Doxorubicin—Paraesthesia—Methotrexate—colon cancer	1.29e-05	0.000268	CcSEcCtD
Doxorubicin—Dyspnoea—Methotrexate—colon cancer	1.28e-05	0.000266	CcSEcCtD
Doxorubicin—Somnolence—Methotrexate—colon cancer	1.28e-05	0.000265	CcSEcCtD
Doxorubicin—Dizziness—Capecitabine—colon cancer	1.28e-05	0.000265	CcSEcCtD
Doxorubicin—Dyspepsia—Methotrexate—colon cancer	1.27e-05	0.000262	CcSEcCtD
Doxorubicin—Decreased appetite—Methotrexate—colon cancer	1.25e-05	0.000259	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Methotrexate—colon cancer	1.24e-05	0.000257	CcSEcCtD
Doxorubicin—Fatigue—Methotrexate—colon cancer	1.24e-05	0.000257	CcSEcCtD
Doxorubicin—Pain—Methotrexate—colon cancer	1.23e-05	0.000255	CcSEcCtD
Doxorubicin—Vomiting—Capecitabine—colon cancer	1.23e-05	0.000255	CcSEcCtD
Doxorubicin—Rash—Capecitabine—colon cancer	1.22e-05	0.000253	CcSEcCtD
Doxorubicin—Dermatitis—Capecitabine—colon cancer	1.22e-05	0.000252	CcSEcCtD
Doxorubicin—Headache—Capecitabine—colon cancer	1.21e-05	0.000251	CcSEcCtD
Doxorubicin—Feeling abnormal—Methotrexate—colon cancer	1.19e-05	0.000246	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Methotrexate—colon cancer	1.18e-05	0.000244	CcSEcCtD
Doxorubicin—Nausea—Capecitabine—colon cancer	1.15e-05	0.000238	CcSEcCtD
Doxorubicin—Urticaria—Methotrexate—colon cancer	1.14e-05	0.000237	CcSEcCtD
Doxorubicin—Body temperature increased—Methotrexate—colon cancer	1.14e-05	0.000236	CcSEcCtD
Doxorubicin—Abdominal pain—Methotrexate—colon cancer	1.14e-05	0.000236	CcSEcCtD
Doxorubicin—Hypersensitivity—Methotrexate—colon cancer	1.06e-05	0.00022	CcSEcCtD
Doxorubicin—Asthenia—Methotrexate—colon cancer	1.03e-05	0.000214	CcSEcCtD
Doxorubicin—Pruritus—Methotrexate—colon cancer	1.02e-05	0.000211	CcSEcCtD
Doxorubicin—Diarrhoea—Methotrexate—colon cancer	9.86e-06	0.000204	CcSEcCtD
Doxorubicin—Dizziness—Methotrexate—colon cancer	9.53e-06	0.000197	CcSEcCtD
Doxorubicin—Vomiting—Methotrexate—colon cancer	9.16e-06	0.00019	CcSEcCtD
Doxorubicin—Rash—Methotrexate—colon cancer	9.08e-06	0.000188	CcSEcCtD
Doxorubicin—Dermatitis—Methotrexate—colon cancer	9.07e-06	0.000188	CcSEcCtD
Doxorubicin—Headache—Methotrexate—colon cancer	9.02e-06	0.000187	CcSEcCtD
Doxorubicin—Nausea—Methotrexate—colon cancer	8.56e-06	0.000177	CcSEcCtD
Doxorubicin—TOP2A—Cell Cycle—EP300—colon cancer	4.44e-06	0.000155	CbGpPWpGaD
Doxorubicin—NOS1—Disease—EP300—colon cancer	4.41e-06	0.000154	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.38e-06	0.000153	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle, Mitotic—MYC—colon cancer	4.32e-06	0.000151	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CASP3—colon cancer	4.32e-06	0.00015	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—KRAS—colon cancer	4.3e-06	0.00015	CbGpPWpGaD
Doxorubicin—NOS1—Disease—SRC—colon cancer	4.29e-06	0.00015	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.26e-06	0.000148	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—PIK3CA—colon cancer	4.24e-06	0.000148	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CCND1—colon cancer	4.2e-06	0.000146	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CTNNB1—colon cancer	4.16e-06	0.000145	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—AKT1—colon cancer	4.16e-06	0.000145	CbGpPWpGaD
Doxorubicin—NOS1—Disease—NRAS—colon cancer	4.13e-06	0.000144	CbGpPWpGaD
Doxorubicin—NOS3—Disease—APC—colon cancer	4.09e-06	0.000143	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CDKN1A—colon cancer	4.06e-06	0.000142	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PPARG—colon cancer	4.06e-06	0.000142	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	4.06e-06	0.000141	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PTGS2—colon cancer	4e-06	0.00014	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—PIK3CA—colon cancer	3.95e-06	0.000138	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.94e-06	0.000137	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PPARG—colon cancer	3.92e-06	0.000137	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—EP300—colon cancer	3.87e-06	0.000135	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—MYC—colon cancer	3.87e-06	0.000135	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—ABCB1—colon cancer	3.86e-06	0.000135	CbGpPWpGaD
Doxorubicin—NOS3—Disease—BRAF—colon cancer	3.85e-06	0.000134	CbGpPWpGaD
Doxorubicin—NOS1—Disease—MYC—colon cancer	3.85e-06	0.000134	CbGpPWpGaD
Doxorubicin—NOS1—Disease—TGFB1—colon cancer	3.84e-06	0.000134	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—TP53—colon cancer	3.82e-06	0.000133	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—TYMS—colon cancer	3.79e-06	0.000132	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.78e-06	0.000132	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	3.77e-06	0.000131	CbGpPWpGaD
Doxorubicin—NOS1—Disease—EGFR—colon cancer	3.76e-06	0.000131	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—SRC—colon cancer	3.76e-06	0.000131	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—ABCB1—colon cancer	3.7e-06	0.000129	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—FGFR3—colon cancer	3.7e-06	0.000129	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—AKT1—colon cancer	3.69e-06	0.000129	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—AKT1—colon cancer	3.69e-06	0.000129	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PTGS2—colon cancer	3.68e-06	0.000128	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	3.67e-06	0.000128	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—VEGFA—colon cancer	3.66e-06	0.000128	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—HRAS—colon cancer	3.65e-06	0.000127	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PPARG—colon cancer	3.64e-06	0.000127	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—TYMS—colon cancer	3.63e-06	0.000127	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	3.63e-06	0.000127	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—NRAS—colon cancer	3.62e-06	0.000126	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—PIK3CA—colon cancer	3.61e-06	0.000126	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CTNNB1—colon cancer	3.58e-06	0.000125	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.56e-06	0.000124	CbGpPWpGaD
Doxorubicin—NOS1—Disease—KRAS—colon cancer	3.55e-06	0.000124	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	3.55e-06	0.000124	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CDKN1A—colon cancer	3.5e-06	0.000122	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—AKT1—colon cancer	3.47e-06	0.000121	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.44e-06	0.00012	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—APC—colon cancer	3.39e-06	0.000118	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	3.37e-06	0.000118	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—MYC—colon cancer	3.37e-06	0.000117	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—PIK3CA—colon cancer	3.36e-06	0.000117	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TGFB1—colon cancer	3.36e-06	0.000117	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EP300—colon cancer	3.33e-06	0.000116	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PPARG—colon cancer	3.31e-06	0.000115	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—EGFR—colon cancer	3.3e-06	0.000115	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CTNNB1—colon cancer	3.29e-06	0.000115	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	3.28e-06	0.000114	CbGpPWpGaD
Doxorubicin—NOS1—Disease—PIK3CA—colon cancer	3.26e-06	0.000114	CbGpPWpGaD
Doxorubicin—NOS2—Disease—SRC—colon cancer	3.24e-06	0.000113	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—AKT1—colon cancer	3.23e-06	0.000112	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CDKN1A—colon cancer	3.22e-06	0.000112	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CHST5—colon cancer	3.21e-06	0.000112	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ODC1—colon cancer	3.21e-06	0.000112	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	3.2e-06	0.000111	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTGS2—colon cancer	3.19e-06	0.000111	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—BRAF—colon cancer	3.19e-06	0.000111	CbGpPWpGaD
Doxorubicin—TOP2A—Cell Cycle—TP53—colon cancer	3.17e-06	0.000111	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—FGFR3—colon cancer	3.12e-06	0.000109	CbGpPWpGaD
Doxorubicin—NOS2—Disease—NRAS—colon cancer	3.11e-06	0.000109	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—KRAS—colon cancer	3.11e-06	0.000109	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTGS2—colon cancer	3.11e-06	0.000108	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTGS2—colon cancer	3.08e-06	0.000107	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EP300—colon cancer	3.06e-06	0.000107	CbGpPWpGaD
Doxorubicin—NOS1—Disease—HRAS—colon cancer	3.02e-06	0.000105	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—SRC—colon cancer	2.97e-06	0.000104	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.96e-06	0.000103	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—AKT1—colon cancer	2.95e-06	0.000103	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	2.94e-06	0.000103	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	2.93e-06	0.000102	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.92e-06	0.000102	CbGpPWpGaD
Doxorubicin—NOS2—Disease—MYC—colon cancer	2.9e-06	0.000101	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ABCB1—colon cancer	2.9e-06	0.000101	CbGpPWpGaD
Doxorubicin—NOS2—Disease—TGFB1—colon cancer	2.89e-06	0.000101	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	2.88e-06	0.0001	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—APC—colon cancer	2.87e-06	9.99e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.86e-06	9.99e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTGS2—colon cancer	2.86e-06	9.99e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—NRAS—colon cancer	2.86e-06	9.98e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—PIK3CA—colon cancer	2.86e-06	9.97e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—TYMS—colon cancer	2.85e-06	9.92e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EGFR—colon cancer	2.84e-06	9.89e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ABCB1—colon cancer	2.8e-06	9.77e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.8e-06	9.75e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CTNNB1—colon cancer	2.78e-06	9.7e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—colon cancer	2.77e-06	9.65e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—TYMS—colon cancer	2.75e-06	9.6e-05	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—AKT1—colon cancer	2.75e-06	9.58e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	2.72e-06	9.47e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—FGFR3—colon cancer	2.72e-06	9.47e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CDKN1A—colon cancer	2.72e-06	9.47e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—BRAF—colon cancer	2.69e-06	9.39e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PPARG—colon cancer	2.68e-06	9.36e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—KRAS—colon cancer	2.68e-06	9.35e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—AKT1—colon cancer	2.67e-06	9.3e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—MYC—colon cancer	2.67e-06	9.29e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—TGFB1—colon cancer	2.66e-06	9.27e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—EP300—colon cancer	2.66e-06	9.26e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—HRAS—colon cancer	2.65e-06	9.23e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EGFR—colon cancer	2.61e-06	9.09e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTGS2—colon cancer	2.6e-06	9.08e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EP300—colon cancer	2.58e-06	9.01e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PPARG—colon cancer	2.57e-06	8.97e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—EP300—colon cancer	2.56e-06	8.93e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ABCB1—colon cancer	2.55e-06	8.89e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—SRC—colon cancer	2.51e-06	8.76e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—TYMS—colon cancer	2.5e-06	8.73e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	2.5e-06	8.7e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—APC—colon cancer	2.49e-06	8.7e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—KRAS—colon cancer	2.46e-06	8.59e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PIK3CA—colon cancer	2.46e-06	8.59e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—NRAS—colon cancer	2.42e-06	8.43e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.41e-06	8.42e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CASP3—colon cancer	2.39e-06	8.34e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—EP300—colon cancer	2.38e-06	8.3e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—BRAF—colon cancer	2.34e-06	8.18e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—AKT1—colon cancer	2.34e-06	8.15e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCND1—colon cancer	2.33e-06	8.11e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CTNNB1—colon cancer	2.3e-06	8.04e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—HRAS—colon cancer	2.28e-06	7.94e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PIK3CA—colon cancer	2.26e-06	7.89e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MYC—colon cancer	2.25e-06	7.85e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CDKN1A—colon cancer	2.25e-06	7.85e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—TGFB1—colon cancer	2.25e-06	7.83e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EGFR—colon cancer	2.2e-06	7.68e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.19e-06	7.64e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—EP300—colon cancer	2.16e-06	7.55e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EP300—colon cancer	2.14e-06	7.47e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.12e-06	7.39e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTGS2—colon cancer	2.11e-06	7.36e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—HRAS—colon cancer	2.09e-06	7.3e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—SRC—colon cancer	2.08e-06	7.26e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—KRAS—colon cancer	2.08e-06	7.26e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.04e-06	7.11e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—colon cancer	2.03e-06	7.07e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTGS2—colon cancer	2.02e-06	7.06e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CASP3—colon cancer	2.02e-06	7.04e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PPARG—colon cancer	2.02e-06	7.03e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—AKT1—colon cancer	2.01e-06	7.01e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NRAS—colon cancer	2e-06	6.99e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCND1—colon cancer	1.97e-06	6.86e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PIK3CA—colon cancer	1.96e-06	6.85e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PPARG—colon cancer	1.95e-06	6.8e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CTNNB1—colon cancer	1.95e-06	6.79e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PIK3CA—colon cancer	1.91e-06	6.67e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CDKN1A—colon cancer	1.9e-06	6.63e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PIK3CA—colon cancer	1.9e-06	6.61e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTGS2—colon cancer	1.89e-06	6.6e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ABCB1—colon cancer	1.87e-06	6.52e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MYC—colon cancer	1.87e-06	6.51e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TGFB1—colon cancer	1.86e-06	6.49e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—AKT1—colon cancer	1.85e-06	6.45e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—TYMS—colon cancer	1.84e-06	6.4e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EGFR—colon cancer	1.83e-06	6.37e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EP300—colon cancer	1.81e-06	6.31e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PPARG—colon cancer	1.77e-06	6.19e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—HRAS—colon cancer	1.77e-06	6.17e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PIK3CA—colon cancer	1.76e-06	6.14e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—SRC—colon cancer	1.76e-06	6.14e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—EP300—colon cancer	1.76e-06	6.12e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—KRAS—colon cancer	1.72e-06	6.01e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—colon cancer	1.71e-06	5.98e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CTNNB1—colon cancer	1.69e-06	5.91e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NRAS—colon cancer	1.69e-06	5.9e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—EP300—colon cancer	1.68e-06	5.87e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CDKN1A—colon cancer	1.66e-06	5.77e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—AKT1—colon cancer	1.6e-06	5.6e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PIK3CA—colon cancer	1.6e-06	5.58e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTGS2—colon cancer	1.59e-06	5.53e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PIK3CA—colon cancer	1.58e-06	5.53e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MYC—colon cancer	1.58e-06	5.5e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EP300—colon cancer	1.58e-06	5.49e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TGFB1—colon cancer	1.57e-06	5.49e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—AKT1—colon cancer	1.56e-06	5.45e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—AKT1—colon cancer	1.55e-06	5.4e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EGFR—colon cancer	1.54e-06	5.38e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTGS2—colon cancer	1.53e-06	5.35e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—colon cancer	1.53e-06	5.35e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—SRC—colon cancer	1.53e-06	5.34e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NRAS—colon cancer	1.47e-06	5.14e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—HRAS—colon cancer	1.47e-06	5.11e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KRAS—colon cancer	1.46e-06	5.08e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—AKT1—colon cancer	1.44e-06	5.02e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS2—colon cancer	1.4e-06	4.87e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MYC—colon cancer	1.37e-06	4.79e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TGFB1—colon cancer	1.37e-06	4.77e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TYMS—colon cancer	1.35e-06	4.72e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EGFR—colon cancer	1.34e-06	4.68e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CA—colon cancer	1.34e-06	4.67e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—EP300—colon cancer	1.32e-06	4.6e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—AKT1—colon cancer	1.31e-06	4.56e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PPARG—colon cancer	1.3e-06	4.53e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ABCB1—colon cancer	1.3e-06	4.53e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CA—colon cancer	1.3e-06	4.53e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—colon cancer	1.3e-06	4.52e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—AKT1—colon cancer	1.29e-06	4.51e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TYMS—colon cancer	1.28e-06	4.45e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—EP300—colon cancer	1.28e-06	4.45e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KRAS—colon cancer	1.27e-06	4.42e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CA—colon cancer	1.25e-06	4.34e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HRAS—colon cancer	1.24e-06	4.32e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CA—colon cancer	1.17e-06	4.06e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—EP300—colon cancer	1.16e-06	4.05e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—AKT1—colon cancer	1.09e-06	3.81e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HRAS—colon cancer	1.08e-06	3.76e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—AKT1—colon cancer	1.06e-06	3.7e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS2—colon cancer	1.02e-06	3.57e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—AKT1—colon cancer	1.02e-06	3.55e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CA—colon cancer	9.76e-07	3.4e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PPARG—colon cancer	9.59e-07	3.34e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—AKT1—colon cancer	9.52e-07	3.32e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CA—colon cancer	9.44e-07	3.29e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PPARG—colon cancer	9.04e-07	3.15e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CA—colon cancer	8.59e-07	2.99e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—EP300—colon cancer	8.51e-07	2.97e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ABCB1—colon cancer	8.49e-07	2.96e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TYMS—colon cancer	8.34e-07	2.91e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—AKT1—colon cancer	7.97e-07	2.78e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—AKT1—colon cancer	7.71e-07	2.69e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS2—colon cancer	7.55e-07	2.63e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS2—colon cancer	7.11e-07	2.48e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—AKT1—colon cancer	7.01e-07	2.45e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CA—colon cancer	6.29e-07	2.19e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—EP300—colon cancer	6.28e-07	2.19e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—EP300—colon cancer	5.91e-07	2.06e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PPARG—colon cancer	5.91e-07	2.06e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AKT1—colon cancer	5.14e-07	1.79e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS2—colon cancer	4.65e-07	1.62e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CA—colon cancer	4.64e-07	1.62e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CA—colon cancer	4.37e-07	1.53e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—EP300—colon cancer	3.87e-07	1.35e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKT1—colon cancer	3.79e-07	1.32e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKT1—colon cancer	3.57e-07	1.25e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CA—colon cancer	2.86e-07	9.97e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKT1—colon cancer	2.34e-07	8.15e-06	CbGpPWpGaD
